The authors noted that apathy is very common and progressive among Huntington disease mutation carriers, even during early stages of the disease, and has been associated with decline in general functioning.
Electrical stimulation of the amygdala may boost declarative memory without influencing an emotional response.
The HD-associated CAG repeat with 36 or more repeats was found in 18 individuals.
The FDA has accepted Teva's New Drug Application for deutetrabenazine to treat chorea associated with Huntington's disease.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Cost-Effectiveness of Atomoxetine for Treating Children with ADHD
- Efficacy of Drugs for Psychosis, Relapse Prevention for Bipolar Depression, Mania
- No Evidence of Cognitive Impairment With Lisdexamfetamine Dimesylate in ADHD
- Differential Testosterone Levels in Men, Women With Schizophrenia
- Intervention Improves Quality of Life, Agitation in Nursing Home Patients With Dementia
- Substance-Induced Psychosis Associated With Development of Schizophrenia, Bipolar Disorder
- Neuropsychiatric Events May Be Linked to Nitrated Nucleosome Levels in Lupus
- New APA Guideline Recommendation for Treatment of Alcohol Use Disorder
- Reducing PTSD Symptoms: Propranolol Before Reactivation Therapy
- Cannabis Use Associated With Subsequent Psychotic Experiences in Adolescents
- Antidepressants More Effective Than Placebo for Acute Depression in Adults
- Positive Beliefs About Age May Protect Older Adults Against Dementia
- Electrical Stimulation of Amygdala May Improve Long-Term Memory
- Negative Symptoms of Schizophrenia May Be Reduced With MIN-101
- Apathy: An Important Predictor of Employment in Huntington Disease